Egis in the World
Egis ’products are available in 61 countries.
Our portfolio contains 634 products. Our highlighted therapeutical areas are the cardiovascular system, the central nervous system and the respiratory system.Learn more
Our products are available in 61 countriesClick here to learn more
Egis activities extend to every field of the pharmaceutical value chainClick here to learn more
Innovation is one of the pillars of our strategy. We devote approximately EUR 45 million to research and development.Click here to learn more
Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.
The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.